Search
Video
Advances in GI Cancer Care: How to Consider the Latest Drugs and Strategies
In this new edition of the Cancer Center Live Series, three UCSF specialists present exciting updates on difficult-to-treat gastrointestinal malignancies, including pancreatic cancer, peritoneal metastases and advanced biliary tract cancers.
News
Radioligand Therapy Plus Pembrolizumab May Benefit Patients with Advanced Prostate Cancer
Immune checkpoint inhibitors have demonstrated limited efficacy in treating prostate cancer. Efforts to improve outcomes with combination therapies have mostly failed to demonstrate improvements compared to other types of cancer.
News
UCSF Cancer Researcher Thomas Martin Receives $4.6 million CIRM Grant
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T cell therapy for multiple myeloma, the second most common malignancy among blood cancers.
News
Can What Works to Treat Cancer Work for Diabetes?
To live with type 1 diabetes is to be ruled by relentless routine. Food must be carefully monitored, and the only treatment, subcutaneous insulin, is burdensome...
Document
Cancer Immunotherapy Toxicity Evaluation (CITE) Program
UCSF Health’s new Cancer Immunotherapy Toxicity Evaluation (CITE) Program is a valuable resource for both patient care and provider consults.
News
A Novel Approach Towards a Vaccine for Relapsing Acute Myeloid Leukemia: Q&A with Dr. Karin Gaensler
There is a major clinical unmet need for effective and safe therapies to increase progression-free and overall survival in older individuals with leukemia whose prognosis is grim.
News
Can Lymph Nodes Boost the Success of Cancer Immunotherapy?
New data from a clinical trial show therapies may activate lymph nodes to produce tumor-tackling T cells.
News
First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial.
Video
Focused Cancer Updates: Neoadjuvant Therapy for Breast Cancer and Managing Immunotherapy Toxicity
An expert panel delivers news to inform therapy and monitoring decisions, including a look at how the I-SPY 2 trial is accelerating evaluation of promising agents in high-risk breast cancer.
News
UCSF Surgical Oncologists Present Clinical Findings at International Conference
The latest advances in surgical cancer care and research were showcased at the Society of Surgical Oncology’s (SSO) Annual Meeting, the International Conference on Surgical Cancer Care. The meeting was held in Boston, from March 22 – 25, 2023.
News
Killing Pancreatic Cancer with T Cells that Turbocharge Themselves
Novel Immunotherapy Pumps Out Cancer-Killing Cytokines Only Inside the Tumor
News
Drug Turns Cancer Gene Into "Eat Me" Flag for Immune System
UCSF-led study shows promising pre-clinical results in killing cancer cells resistant to current KRAS-targeted treatments.
News
“CAR Pooling” Screens Identify Most Effective Cancer Immunotherapy Cells
New approach by UCSF researchers analyzes how well different re-engineered T cells work against cancer.
News
International Conference Features UCSF Breast Cancer Experts
Breast cancer experts from UCSF Health presented new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most prestigious breast cancer conference.
News
International Hematologic Conference Features UCSF Health Experts
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 64th Annual Meeting and Exposition.
News
UCSF Research Instrumental in Approval of Breakthrough Diabetes Therapy
The US Food and Drug Administration (FDA) recently approved the use of a new drug Teplizumab, an immunotherapy drug which has been shown to significantly delay the onset of type 1 diabetes.
News
Research Reveals Mechanisms at Work in Progression of Pancreatic Cysts to Pancreatic Cancer
Tumor Immune Microenvironments May Provide Clues to Future Therapies
News
UCSF Sheds Light on the Reasons Behind Sex Differences in Myocarditis
This study suggests mechanisms behind why myocarditis associated with cancer immunotherapies may occur more frequently in female patients.
News
Autoantibody for Acquired Lipodystrophy Identified, Bringing Hope for Therapeutics
UCSF investigators have found an autoantibody biomarker for acquired lipodystrophy, paving the way for novel treatment options for this complex condition, which causes adipose tissue loss and metabolic complications.
News
Renowned Expert to Lead UCSF’s Hematology and Oncology Division
Krishna Komanduri, MD, an international leader in hematology-oncology, transplantation and cellular immunotherapy, is the new chief of UCSF’s Division of Hematology and Oncology.
News
UCSF’s Dr. Mitchel Berger on the Cancer Moonshot Relaunch
On Feb. 2, 2022, Mitchel Berger, MD, neurosurgeon and director of the UCSF Brain Tumor Center, attended the relaunch of the White House’s Cancer Moonshot initiative at the invitation of President Joe Biden and Dr. Jill Biden.
News
Immune Cells Leave Fingerprints on Tumors Metastasized to the Brain Offering Clues to Future Therapies
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types. Their findings, published the February 17 issue of CELL, provide a potential roadmap for metastatic tumor formation that could be used to design therapies to improve the treatment of metastasized patients.
News
Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies
Using data from over 300 patient tumors, UCSF researchers have described 12 classes of “immune archetypes” to classify cancer tumors. Their findings, published today in CELL, reveal that cancers from different parts of the body are immunologically similar to one another. These classifications provide unique strategies for enhancing each patient’s choice of cancer immunotherapies.
News
International Hematologic Conference Features UCSF Health Experts
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 63rd Annual Meeting and Exposition. This year’s meeting will be held in Atlanta, Georgia – and virtually – from December 11-14, 2021.
